Novavax's COVID-19 vaccine produced a safe immune response in Phase 1 human trials, data shows
With funding it received from the US government, Novavax is aiming to deliver 100 million doses of its vaccine to Americans by end of 2020.
Along with some mild side effects, a potential COVID-19 vaccine from the biotech major Novavax prompted a promising immune response in a limited early trial with 131 healthy trial participants, who were all between ages 18-59.
The results of the early (Phase 1) trial, published Thursday in a press statement by the company, shows that the vaccine candidate (called NVX-CoV2373) was well-tolerated and found safe in all volunteers. An immune response was also generated in all the trial volunteers, and the antibodies were able to neutralize the SARS-CoV-2 virus in 100 percent of cases, the statement said.
The best responses came from volunteers who received two injections of the vaccine candidate, 21 days apart, along with an adjuvant that amplifies the immune response triggered by the vaccine. 35 days after the shot, the trial volunteers seemed to have roughly four times as many neutralizing antibodies as a group of 32 patients who had recovered from COVID-19 without the vaccine.
However, the shots were not without its side effects. After the first dose of the vaccine, many volunteers reported tenderness and pain near the region of the shot itself, and a few reported systemic effects like headache, fatigue and muscle pain. After the second dose, given 21 days after the first, symptoms the volunteers reported were minor, and lasted two days on average out of the 28 days over which the volunteers were monitored.
Despite this, experts have called the vaccine among the most promising ones at the human trial stage.
In animal trials of the Novavax NVX‑CoV2373 vaccine in macaques, the shot offered immunity and prevented the SARS-CoV-2 virus from replicating in the upper and lower respiratory tract. The study pre-published in medRxiv on 6 August and submitted for peer-review, claims that these findings are strong indication of the vaccine's potential in reducing COVID-19 transmission. There was also no indication of the vaccine enhancing COVID-19 disease itself, the report added.
Novavax was given a $1.6 billion by the US government as part of Operation Warp Speed (OWS) – an effort to deliver millions of doses of a safe, effective vaccine for COVID-19 to the American population. This funding, Novavax said, is being used to finish clinical development of the vaccine (including Phase 3 trials), to set up large-scale manufacturing, and deliver 100 million doses of the NVX‑CoV2373 vaccine by end of 2020.
The country had previously cited lack of sufficient data to greenlight the vaccine for older people
JnJ's vaccine appears to be less prone than Pfizer-BioNTech's and Moderna's, to trigger the kinds of side effects that require monitoring.
Pfizer-BioNTech and Moderna plan to gradually test their vaccines in younger and younger age groups.